GlassScriptPhysician profile
Anushayanthan Alfred
NPI 1871765859
$7,796.40
in general payments reported to CMS, 2019-2025
32 companies · $2,375 in 2025
The $2,375 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $344 · 2021: $414 · 2022: $527 · 2023: $1,920 · 2024: $1,569 · 2025: $2,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,403 · Travel and Lodging: $282 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,402.53 |
| Travel and Lodging | $282.26 |
| Education | $178.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,534.85 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Novartis Pharmaceuticals Corporation | $880.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $798.10 | 2019-2025 | Lokelma, Farxiga |
| Vantive US Healthcare LLC | $514.51 | 2025 | Renal - Acute |
| Glaxosmithkline, LLC. | $393.81 | 2020-2024 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $380.83 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $359.95 | 2019-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $282.76 | 2020-2025 | Terlivaz, Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $263.60 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $257.45 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $238.09 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $205.54 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $176.45 | 2021-2025 | Rayaldee |
| Baxter Healthcare | $174.38 | 2019-2024 | Renal - Acute |
| Novo Nordisk INC | $155.64 | 2023-2025 | Wegovy, Ozempic |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $149.98 | 2025 | Tarpeyo |
| Abbvie INC. | $125.38 | 2023 | Avycaz |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.03 | 2022-2025 | Jardiance |
| Vifor Pharma, INC. | $113.49 | 2019-2025 | Veltassa |
| Bard Peripheral Vascular, INC. | $105.40 | 2020 | |
| Akebia Therapeutics INC | $86.92 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.97 | 2023-2024 | |
| Ardelyx, INC. | $56.23 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $47.08 | 2024-2025 | Velphoro, Velphoro |
| Ultragenyx Pharmaceutical INC. | $42.77 | 2021-2024 | Crysvita |
| Aurinia Pharma U.S., INC. | $42.25 | 2021 | |
| Genzyme Corporation | $24.23 | 2025 | |
| Mallinckrodt Enterprises LLC | $23.37 | 2019 | |
| Cycle Pharmaceuticals INC | $23.14 | 2025 | Venxxiva |
| Pfizer INC. | $15.64 | 2024 | |
| Daiichi Sankyo INC. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anushayanthan Alfred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.